Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

An update on Cuban biotech

Nature Biotechnology volume 42, pages 1768–1770 (2024)Cite this article

Subjects

Cuba provides a rare example of a publicly owned biotech sector in a low-income country. Since its founding in 1986, Cuba’s Center for Genetic Engineering and Biotechnology (CIGB) has overseen the development of the country’s biopharmaceutical sector, from the initial conception of a drug through preclinical studies, clinical trials, licensing, manufacturing and export. We outlined the achievements of the CIGB in a 2007 Correspondence in this journal1. Here we update that account to describe the subsequent course of biotech in Cuba. The CIGB has continued to shepherd the development of drugs and vaccines for cancer, infectious disease and other conditions and to date has obtained regulatory approvals in more than 50 countries (Table 1). Notably, during the first years of the COVID-19 pandemic, when vaccines were largely unavailable in developing countries, the CIGB manufactured a subunit vaccine (CIGB 66) based on well-established technologies2. The vaccine was approved by the Cuban regulatory agency and in five foreign countries. The CIGB also demonstrated the efficacy of a pre-existing Cuban intravenous anti-inflammatory drug, CIGB 258, in patients with COVID-19 (ref. 3).

Table 1 Biomedical projects of the CIGBa
Full size table

The CIGB is a biotechnology research institute within BioCubaFarma, a holding group of government-owned enterprises. Approximately 400 researchers are directly involved in R&D. The CIGB’s board prioritizes which R&D projects to pursue by considering a range of factors, including national public health priorities, in-house scientific expertise, the facilities required for large-scale production, and market research on potential patents and sales in foreign countries. Projects are coordinated by an Innovation Committee consisting of experts linked to research institutes, biotechnology companies, universities, academics and officials of the Ministry of Public Health. A weekly meeting of the Innovation Committee, attended by the president of Cuba, aims to achieve consensus on R&D projects. Most projects are approved by the Ministry of Science, Technology, and Environment. Public health priorities are identified by the Ministry of Health and largely reflect disease incidence in Cuba (Table 2).

Table 2 Top 30 priorities of the Cuban health system in 2023
Full size table

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. López, E. et al. Nat. Biotechnol. 25, 1215–1216 (2007).

    Article  PubMed  Google Scholar 

  2. Hernández-Bernal, F. et al. Lancet Reg. Health Am. 21, 100497 (2023).

    PubMed  PubMed Central  Google Scholar 

  3. Venegas-Rodríguez, R. et al. PLoS One 18, e0281111 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Evans, R. et al. Front. Oncol. 12, 958043 (2022).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the CIGB, La Habana, Cuba.

Author information

Authors and Affiliations

  1. Department of Intellectual Property, Center for Genetic Engineering and Biotechnology, La Habana, Cuba

    José A. Buxadó & Raimundo Ubieta Gómez

  2. Business Development, Center for Genetic Engineering and Biotechnology, La Habana, Cuba

    Miladys Limonta Fernández

  3. Biomedical Research, Center for Genetic Engineering and Biotechnology, La Habana, Cuba

    Gerardo E. Guillén Nieto

  4. Center for Genetic Engineering and Biotechnology, La Habana, Cuba

    Marta Ayala Ávila

Authors
  1. José A. Buxadó
    View author publications

    Search author on:PubMed Google Scholar

  2. Miladys Limonta Fernández
    View author publications

    Search author on:PubMed Google Scholar

  3. Gerardo E. Guillén Nieto
    View author publications

    Search author on:PubMed Google Scholar

  4. Raimundo Ubieta Gómez
    View author publications

    Search author on:PubMed Google Scholar

  5. Marta Ayala Ávila
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to José A. Buxadó.

Ethics declarations

Competing interests

Authors are employees of the CIGB, which develops, manufactures and markets biotech products.

Supplementary information

Supplementary Table 1

English-language papers on phase 2 and 3 clinical trials and postmarketing analysis for the products in Table 1

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Buxadó, J.A., Limonta Fernández, M., Guillén Nieto, G.E. et al. An update on Cuban biotech. Nat Biotechnol 42, 1768–1770 (2024). https://doi.org/10.1038/s41587-024-02458-y

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41587-024-02458-y

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing